In Brief: Bristol-Myers Squibb
Executive Summary
Bristol-Myers Squibb: Maxipime (cefepime) will be reviewed for treatment of febrile episodes in neutropenic patients March 5 by the Anti-Infective Drugs Advisory Committee at a meeting held at the Ramada Inn in Bethesda, Md. The open public hearing begins at 8:30. In the afternoon of March 5 and all of March 6 and 7, committee will discuss document to industry on evaluability criteria for review of anti-microbials at the Division of Anti-Infective Drug Products. Copies of the draft document can be obtained two weeks before the meeting by calling (301) 827-4573. On March 6 and 7, the meeting will be held at the Bethesda Holiday Inn...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth